Want to see HK:1501 full AI Analyst Report?
Shanghai Kindly Medical Instruments Co., Ltd. Class H (1501) AI Stock Analysis
Top Page
Shanghai Kindly Medical Instruments Co., Ltd. Class H
(HKEX:1501)
The score is driven primarily by solid underlying operating performance and improved 2025 cash generation, but is held back by the sharp increase in leverage and a weakening technical backdrop (trading below major moving averages with soft momentum). Valuation is moderate with a low dividend yield, offering only limited offset.
Shanghai Kindly Medical Instruments Co., Ltd. Class H (1501) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 4.93B
- Dividend Yield
- 0.87%
- Average Volume (3M)
- 213.51K
- Price to Earnings (P/E)
- 21.6
- Beta (1Y)
- -0.02
- Revenue Growth
- 34.94%
- EPS Growth
- 12.99%
- Country
- Hong Kong
- Employees
- 2,180
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Instruments & Supplies
Shanghai Kindly Medical Instruments Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Shanghai Kindly Medical Instruments Co., Ltd., founded in 2006 and based in Shanghai, China, focuses on the research, development, production, and international sales of cardiovascular interventional medical devices. The company's products reach cust...
How the Company Makes Money
The company primarily makes money by selling medical devices and related disposable/consumable products to healthcare providers (e.g., hospitals and clinics), generating revenue on a per-unit basis through product shipment/recognized sales. Revenue i...
Shanghai Kindly Medical Instruments Co., Ltd. Class H Financial Statement Overview
Summary
Solid revenue growth and healthy profitability (2025 net margin ~20.5%, EBIT margin ~20.7%) are tempered by multi-year margin compression, a sharp 2025 increase in leverage (debt-to-equity ~0.36 vs ~0.14 in 2024), and historically volatile free cash flow despite a strong 2025 rebound.
Income Statement
74PositiveBalance Sheet
67PositiveCash Flow
61Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.19B | 1.07B | 851.95M | 752.84M | 585.88M | 464.68M |
| Gross Profit | 725.48M | 636.79M | 537.66M | 438.07M | 332.49M | 275.75M |
| EBITDA | 386.17M | 362.52M | 292.50M | 225.88M | 166.42M | 174.85M |
| Net Income | 229.06M | 218.79M | 191.91M | 156.46M | 131.71M | 142.96M |
Balance Sheet | ||||||
| Total Assets | 3.87B | 3.13B | 2.26B | 2.03B | 1.83B | 1.62B |
| Cash, Cash Equivalents and Short-Term Investments | 1.32B | 630.81M | 554.51M | 434.40M | 528.27M | 640.55M |
| Total Debt | 716.25M | 716.26M | 243.69M | 94.78M | 48.83M | 13.40M |
| Total Liabilities | 1.03B | 1.04B | 473.39M | 351.25M | 273.23M | 183.63M |
| Stockholders Equity | 2.76B | 2.00B | 1.77B | 1.65B | 1.51B | 1.40B |
Cash Flow | ||||||
| Free Cash Flow | 377.34M | 278.17M | 59.80M | -53.05M | -62.75M | -205.07M |
| Operating Cash Flow | 445.91M | 340.98M | 225.54M | 178.15M | 180.46M | 72.76M |
| Investing Cash Flow | -389.31M | -491.99M | -187.31M | -283.81M | -316.18M | -268.08M |
| Financing Cash Flow | 791.38M | 263.40M | 56.97M | 8.06M | 9.72M | -31.07M |
Shanghai Kindly Medical Instruments Co., Ltd. Class H Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1501, the sentiment is Negative. The current price of 30.00 is below the 20-day moving average (MA) of 31.26, below the 50-day MA of 33.07, and below the 200-day MA of 32.88, indicating a bearish trend. The MACD of -0.91 indicates Positive momentum. The RSI at 39.94 is Neutral, neither overbought nor oversold. The STOCH value of 25.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1501.
Shanghai Kindly Medical Instruments Co., Ltd. Class H Peers Comparison
Overall Rating
HK:360080Outperform
HK:692978Outperform
HK:135866Neutral
HK:669966Neutral- HK:150161Neutral
HK:106659.9Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:3600 | 80Outperform | HKD 6.79B | 9.96 | 20.11% | 3.85% | 12.50% | 44.44% |
| HK:6929 | 78Outperform | HKD 3.08B | 8.88 | 10.50% | 5.35% | 16.25% | 7.80% |
| HK:1358 | 66Neutral | HKD 1.28B | 26.55 | 1.10% | 7.15% | -1.64% | -68.67% |
| HK:6699 | 66Neutral | HKD 13.19B | 39.13 | 8.95% | 1.24% | ― | ― |
| HK:1501 | 61Neutral | HKD 6.34B | 21.57 | 9.64% | 0.87% | 34.94% | 12.99% |
| HK:1066 | 60Neutral | HKD 14.54B | 9.09 | 5.64% | 5.24% | 7.47% | -26.89% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:1501 | Shanghai Kindly Medical Instruments Co., Ltd. Class H | 30.00 | 0.12 | 0.39% | |
| HK:1066 | Shandong Weigao Group Medical Polymer Co Class H | 3.21 | -2.04 | -38.76% | |
| HK:1358 | PW Medtech Group Ltd. | 0.90 | -0.56 | -38.36% | |
| HK:3600 | Modern Dental Group Limited | 7.27 | 2.19 | 43.08% | |
| HK:6699 | Angelalign Technology Inc. | 76.55 | 14.99 | 24.35% | |
| HK:6929 | OrbusNeich Medical Group Holdings Limited | 3.73 | -0.48 | -11.43% |
Shanghai Kindly Medical Instruments Co., Ltd. Class H Corporate Events
Shanghai INT Medical Instruments Wins Shareholder Backing for Board Shake-Up and Governance Changes
Shanghai INT Medical Instruments Co., Ltd. held its first extraordinary general meeting of 2026 in Shanghai, where all directors attended either in person or electronically and the meeting procedures were confirmed to comply with PRC Company Law and...
Shanghai INT Medical Clarifies Board Composition and Committee Roles
Shanghai INT Medical Instruments Co., Ltd. has released an updated list of its board of directors, detailing the composition of executive, non-executive, employee representative, and independent non-executive members. The announcement underscores the...
Shanghai INT Medical Clarifies Sellers in Healthcare Equity Acquisition
Shanghai INT Medical Instruments Co., Ltd., a Hong Kong-listed Chinese medical device maker, operates in the healthcare sector with a focus on medical instruments and related technologies. Its shareholder base includes healthcare-focused and general...
Shanghai INT Medical Instruments Calls EGM to Revamp Board and Governance Framework
Shanghai INT Medical Instruments Co., Ltd., a PRC-incorporated medical device manufacturer listed in Hong Kong under stock code 1501, designs and produces medical instruments from its Shanghai headquarters, supported by a principal office in Hong Kon...
Shanghai INT Medical Reshapes Board as It Prepares Mainland A-Share Listing
Shanghai INT Medical Instruments announced several board changes as it prepares for a mainland A-share listing, including the resignation of non-executive director Wang Ruiqin due to personal work adjustments. The company also disclosed that long-ser...
Shanghai INT Medical Instruments Sets Out Board and Committee Structure
Shanghai INT Medical Instruments Co., Ltd. has detailed the composition of its board of directors, which includes two executive directors, four non-executive directors, an employee representative director and three independent non-executive directors...
Shanghai INT Medical Instruments Boosts Revenue and Margins on Interventional Device Growth
Shanghai INT Medical Instruments reported robust growth for the six months ended 30 June 2026, with revenue rising 29.28% to RMB596.06 million, driven mainly by stronger sales of interventional medical devices. Revenue from these core products climbe...
Shanghai Kindly Medical Sets Board Meeting to Approve Interim Results and Consider Dividend
Shanghai Kindly Medical Instruments Co., Ltd., a PRC-incorporated joint stock company listed in Hong Kong, operates in the medical instruments industry, supplying a range of healthcare-related devices through its subsidiaries. Its board comprises exe...
Shanghai INT Medical Sets Extraordinary General Meeting and Closes Register of Members
Shanghai INT Medical Instruments Co., Ltd. has scheduled its first extraordinary general meeting of 2026 for 24 September, and will temporarily close its register of members from 25 August to 24 September to determine shareholder eligibility. Share t...
Shanghai INT Medical Expands Stake in Target Firm via US$55 Million Indirect Acquisition
Shanghai INT Medical Instruments has agreed, via a wholly owned subsidiary, to acquire 100% of the partnership interests in Shanghai Maoyi for US$55.1 million, which indirectly holds 579,866 series B preferred shares in a target company, equal to abo...
Shanghai INT Medical Grants Performance-Linked H-Share Awards to Executive Director
Shanghai INT Medical Instruments has granted H-share awards under its existing H Share Award and Trust Scheme, which uses company funds for on-market purchases rather than issuing new shares. The awards, which form part of its long-term incentive fra...
Shanghai INT Details Valuation and Compliance for Pulin Medical Stake Acquisition
Shanghai INT Medical Instruments Co., Ltd. has provided further details on its planned acquisition of a 35% equity stake in its non-wholly owned subsidiary, Shanghai Pulin Medical Instruments Co., Ltd., reinforcing its strategic focus on consolidatin...
Shanghai INT Medical Instruments Raises Stake in Target Company via Second Discloseable Acquisition
Shanghai INT Medical Instruments has agreed to further increase its stake in a target healthcare company by acquiring an additional 0.79% of its share capital, comprising 119,545 Series B preferred shares, for US$10 million. This follows its earlier...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 06, 2026